



A partial setback and a possible overreaction

Kosan Biosciences Inc. ([KOSN - news](#)) had discontinued its Phase 2 clinical trial of KOS-862 in hormone refractory prostate cancer. Interim analysis revealed that the drug did not meet the trial's endpoint for the number of patients with a response to therapy, as measured by change in a tumor marker levels. The stock is now down around 0.76 on 6K shares Tuesday morning on Inet.

Kosan Biosciences Inc. traded in a narrow range for the majority of Tuesday's session and closed down by 0.08 at \$6.25. The stock dipped to a 3-month low.

Copyright(c) 2005 RealTimeTraders.com, Inc. All Rights Reserved

The drug is still on for Breast cancer

Trials with KOS-862, however, are continuing to enroll patients in Phase 2 monotherapy in sclinical trial on breast cancer patients. Preliminary data have been accepted for presentation at the San Antonio Breast Cancer Symposium in December 2005. The Phase Ib portion of the **KOS-862 plus Herceptin trial has completed enrollment**, with the Phase 2 component of the trial is expected to initiate enrollment this quarter. Roche expressed confidence in the potential of epothilones as important anticancer agents. Roche continues to actively collaborate with Kosan on the assessment of KOS-862 for breast cancer, as well as KOS-1584, another epothilone compound currently in Phase I clinical testing.

Nevertheless, there will definitely be a negative over reaction through some selling of the stock.

For more news: [Kosan Provides Update on KOS-862 Phase II Program](#)

PROHOST RESEARCH
P.O.BOX 640 429
Oakland Gardens, Ny 11364
Telephone : 516 678 1335
Fax 718 423 2731
E-mail prohost@aol.com.

FORWARD-LOOKING STATEMENT Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: <http://www.sec.gov/consumer/cyberfr.htm>